Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study

Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sandra Huynh, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, Francois Aubin, Brigitte Dreno, Marie Beylot-Barry, Celeste Lebbe, Wendy Lefevre, Julie Delyon
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2020-06-01
Colecção:Cancers
Assuntos:
anti-PD1
targeted therapy
BRAF inhibitor
MEK inhibitor
melanoma
Acesso em linha:https://www.mdpi.com/2072-6694/12/6/1666
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados